GE HealthCare CEO Says Locked-In Chip Prices Aren't 'Realistic' — First Access Is The Goal

CEO Peter Arduini says multi-year supply deals put the company first in line for memory chips as AI demand strains components.

Share
GE HealthCare CEO Says Locked-In Chip Prices Aren't 'Realistic' — First Access Is The Goal

GE HealthCare CEO Peter Arduini said on the company's third-quarter earnings call Wednesday that it has signed multi-year agreements to secure memory chips, while conceding that fixed pricing is out of reach as data-center demand squeezes supply. The company, which makes imaging equipment, patient monitors and diagnostic imaging agents, also raised its full-year adjusted earnings guidance to $4.95 to $5.05 per share, CFO Bill Grogan said.

First in line, not fixed prices

Asked how the chip deals help manage costs, Arduini said AI and data centers have a "big vortex effect" on certain components, and he expects that to last for multiple years. GE HealthCare took an ecosystem approach, he said, and approached suppliers with what it believes was adequate lead time.

"Getting locked in pricing agreements on some of these things isn't probably realistic," Arduini told analysts. What the company achieved, he said, is "being in a favored nation status" in which it is first in line for both supply and price.

He said the company feels good about critical components such as memory chips, but expects the pressure to spread to other components over time. "We're already focused on that," he said.

Chip and oil costs ate into margin

Grogan said margin took a hit in the quarter from memory chip inflation and higher oil prices across the supply chain. Even so, adjusted EBIT margin was 16.6%, up 180 basis points (1.8 percentage points).

Revenue of $5.5 billion rose 6.2% organically, with growth in every segment. Adjusted EPS was $1.34, up 25.1%, and free cash flow reached $793 million, up $310 million from a year earlier. Backlog stood at $23.7 billion, up 12%.

For the full year, Grogan now expects organic revenue growth of about 4%, adjusted EBIT margin of 15.5% to 15.7%, and free cash flow above $1.6 billion.

Other news from the call

GE HealthCare said it plans to acquire Sofie Biosciences, a deal Arduini said would give it a final-mile footprint for U.S. pet radiopharmaceutical supply. It also said Jeannette Bankes, who leads its Patient Care Solutions business, is leaving to be CEO of a non-competitive public company, with Neil Sandy taking over. Arduini said the company is evaluating strategic options for that business, and that the leadership change does not affect the review.

Arduini said the company will show its new AI-enabled products at the Radiological Society of North America meeting in Chicago, which he called a pivotal window for growth in 2027 and 2028.

Sources

More on GE HealthCare

All GE HealthCare (GEHC) coverage →